'Leclaza (Lazertinib)', a non-small cell lung cancer treatment by Yuhan Corporation, the 31st new drug developed in Korea, has passed the first step of reimbursement.

After receiving approval from the Ministry of Food and Drug Safety on January 18, the HIRA's Pharmaceutical Benefits Advisory Committee recognized the appropriateness of reimbursement within 81 days.

When the HIRA notifies the Minister of Health and Welfare of the results of the review, Leclaza will proceed with drug price negotiations for about 60 days with the NHIS at the order of the Minister of Health and Welfare.

When the drug price negotiations with the NHIS are over, the final notification is made through